Biogen is a biotechnology company focused on neurological and neurodegenerative diseases, with established multiple sclerosis therapies and treatments in areas such as spinal muscular atrophy and Alzheimer’s disease. It develops and commercializes specialty biologics and partners on late-stage neuroscience assets. Its customers are primarily specialty physicians, hospitals and payers in markets where high-cost neurology drugs are reimbursed.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 2,431 | — | 240.5 | — |
| Q2 2025 | 2,645.5 | — | 634.8 | — |
| Q3 2025 | 2,534.7 | — | 466.5 | — |
| Q4 2025 | 2,279.4 | — | -48.9 | — |
| Q1 2026 | 2,477.8 | 1.9% | 319.5 | 32.9% |
| Q2 2026 | 2,736 | 3.4% | 97.5 | -84.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Willis Towers Watson Public Limited Company (WTW), Copart, Inc. (CPRT), Zscaler, Inc. (ZS), The Kraft Heinz Company (KHC), Okta, Inc. (OKTA), LPL Financial Holdings Inc. (LPLA)